Lilly signed a multi-program collaboration with Bezos-backed Profluent to co-develop AI-designed site-specific recombinases for genetic medicines; Profluent eligible for an undisclosed upfront, R&D funding, and up to $2.25B in development/commercial milestones plus tiered royalties.
Key facts
AnnouncedApr 28, 2026
ClosedApr 28, 2026
Deal value$2.2B
Deal typeCo-Development
Therapeutic areaGenetic diseases with severe unmet need (multi-indication)
IndicationsGenetic diseases with severe unmet need (multi-indication)
Key assetsAI-designed site-specific recombinases for genetic medicine (multi-program platform)